MX2019013397A - Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina. - Google Patents

Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.

Info

Publication number
MX2019013397A
MX2019013397A MX2019013397A MX2019013397A MX2019013397A MX 2019013397 A MX2019013397 A MX 2019013397A MX 2019013397 A MX2019013397 A MX 2019013397A MX 2019013397 A MX2019013397 A MX 2019013397A MX 2019013397 A MX2019013397 A MX 2019013397A
Authority
MX
Mexico
Prior art keywords
therapeutic agent
lewy body
body disease
disease therapeutic
agent containing
Prior art date
Application number
MX2019013397A
Other languages
English (en)
Inventor
Ishikawa Yukio
Miyamoto Mai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2019013397A publication Critical patent/MX2019013397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un agente terapéutico para enfermedad con cuerpos de Lewy que comprende (S)-7-(2-metoxi-3,5-dimetilpiridin-4-il)-1-( tetrahidrofuran-3-il)-1H-pirazolo[4,3-c]quinolin-4(5H)-ona representada por la fórmula (I) (ver Fórmula) o una sal farmacéuticamente aceptable de la misma.
MX2019013397A 2017-06-01 2018-05-30 Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina. MX2019013397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513727P 2017-06-01 2017-06-01
PCT/JP2018/020650 WO2018221551A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体を含有するレビー小体病治療剤

Publications (1)

Publication Number Publication Date
MX2019013397A true MX2019013397A (es) 2020-02-07

Family

ID=64456542

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013397A MX2019013397A (es) 2017-06-01 2018-05-30 Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.

Country Status (13)

Country Link
US (1) US11311530B2 (es)
EP (1) EP3632438B1 (es)
JP (1) JP7269875B2 (es)
KR (1) KR20200010220A (es)
CN (1) CN110612102A (es)
AU (1) AU2018278422B2 (es)
BR (1) BR112019023552A2 (es)
CA (1) CA3061884A1 (es)
ES (1) ES2961554T3 (es)
IL (1) IL270357B2 (es)
MX (1) MX2019013397A (es)
TW (1) TWI784006B (es)
WO (1) WO2018221551A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909595VA (en) 2017-06-01 2019-11-28 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
CN110603039B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂
MX2019013198A (es) 2017-06-01 2020-01-20 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
US5688803A (en) 1994-05-24 1997-11-18 Hoffmann-La Roche Inc. Tricyclic dicarbonyl derivatives
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
JP2005534713A (ja) 2002-08-07 2005-11-17 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
JPWO2008072778A1 (ja) 2006-12-13 2010-04-02 あすか製薬株式会社 尿路系疾患の処置剤
ES2536906T3 (es) 2006-12-13 2015-05-29 Aska Pharmaceutical Co., Ltd. Derivado de quinoxalina
BRPI0811280B8 (pt) 2007-05-11 2021-05-25 Pfizer compostos amino-heterocíclicos, composição farmacêutica que os compreende e usos dos referidos compostos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2404922B1 (en) 2009-03-05 2016-11-09 Astellas Pharma Inc. Quinoxaline compounds
MA33152B1 (fr) 2009-03-31 2012-03-01 Boehringer Ingelheim Int Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
NZ603725A (en) 2010-08-12 2015-04-24 Boehringer Ingelheim Int 6-cycloalkyl-1,5-dihydro-pyrazolo [3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
MX2013002584A (es) 2010-09-07 2013-04-29 Astellas Pharma Inc Compuesto de pirazoloquinolina.
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
DK2573073T3 (en) 2011-09-26 2015-01-19 Sanofi Sa Pyrazolquinolinonderivater, their preparation and therapeutic use thereof
PE20141557A1 (es) 2011-10-07 2014-11-15 Eisai Randd Man Co Ltd Derivado de pirazoloquinolina
KR101997955B1 (ko) * 2013-04-05 2019-07-08 에자이 알앤드디 매니지먼트 가부시키가이샤 피라졸로퀴놀린 유도체의 염, 및 이의 결정
PE20151718A1 (es) 2013-04-05 2015-11-22 Eisai Randd Man Co Ltd Compuestos piridinilpirazoloquinolina
MX2019013198A (es) 2017-06-01 2020-01-20 Eisai R&D Man Co Ltd Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
CN110603039B (zh) 2017-06-01 2023-02-28 卫材R&D管理有限公司 组合吡唑并喹啉衍生物和美金刚的痴呆治疗剂
SG11201909595VA (en) 2017-06-01 2019-11-28 Eisai R&D Man Co Ltd Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil

Also Published As

Publication number Publication date
WO2018221551A1 (ja) 2018-12-06
BR112019023552A2 (pt) 2020-06-02
JP7269875B2 (ja) 2023-05-09
RU2019135690A (ru) 2021-07-13
JPWO2018221551A1 (ja) 2020-04-02
TW201902479A (zh) 2019-01-16
US11311530B2 (en) 2022-04-26
EP3632438A4 (en) 2020-12-23
TWI784006B (zh) 2022-11-21
IL270357B2 (en) 2024-02-01
IL270357A (es) 2020-02-27
EP3632438B1 (en) 2023-08-23
CA3061884A1 (en) 2019-10-29
AU2018278422B2 (en) 2022-03-17
KR20200010220A (ko) 2020-01-30
ES2961554T3 (es) 2024-03-12
CN110612102A (zh) 2019-12-24
EP3632438A1 (en) 2020-04-08
IL270357B1 (en) 2023-10-01
AU2018278422A1 (en) 2019-11-21
US20200155541A1 (en) 2020-05-21
RU2019135690A3 (es) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2019013397A (es) Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.
MX2019013383A (es) Agente terapeutico para la demencia que combina derivado de pirazoloquinolina y memantina.
SG11201909595VA (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
PH12017502171B1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
MX2021001096A (es) 7-bencil-4-(2-metilbencilo)-2,4,6,7,8,9-hexahidroimidazo [1,2-a]pirido[3,4-e]pirimidin-5(1h)-ona, analogos y sales del mismo y su uso en terapia.
EP3970712A3 (en) Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
MX2018012207A (es) Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
MX2019013198A (es) Composicion farmaceutica que comprende un inhibidor de (s)-7-(2metoxi-3,5-dimetilpiridin-4-il)-1-(tetrahidrofuran-3-il)- 1h-pirazolo[4,3-c]quinolin-4(5h)-ona (pde9).
MX2018012208A (es) Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
PH12016502307A1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
AU2017268006A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
SA519401827B1 (ar) [3، 4- d] مشتق بيريدو بيريميدين وملح مقبول صيدلانياً منه
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
MX2021007247A (es) Derivados de rapamicina.
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
PH12018500980A1 (en) Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor
CO2018002204A2 (es) Agentes antibacteriales que comprenden un pirazino [2,3-b]- [1,4] oxazin-3-ona o un sistema de anillo relacionado
MX2018011592A (es) Compuesto que tiene actividad inhibitoria de idh mutante, metodo de preparacion y usos del mismo.
MX2018010177A (es) Compuestos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxa mida.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502620A1 (en) 6h-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative
MX2021000942A (es) Derivado de lactama condensado.
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
IL283823A (en) 7-phenoxy-n-(3-azabicyclo[3.2.1]octan-8yl-)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine derivatives and related compounds as gamma-secretase inhibitors for the treatment of Alzheimer's disease